PT2178850E - Trazodona e cloridrato de trazodona na forma purificada - Google Patents

Trazodona e cloridrato de trazodona na forma purificada Download PDF

Info

Publication number
PT2178850E
PT2178850E PT08775309T PT08775309T PT2178850E PT 2178850 E PT2178850 E PT 2178850E PT 08775309 T PT08775309 T PT 08775309T PT 08775309 T PT08775309 T PT 08775309T PT 2178850 E PT2178850 E PT 2178850E
Authority
PT
Portugal
Prior art keywords
trazodone
purified form
hydrochloride
trazodone hydrochloride
purified
Prior art date
Application number
PT08775309T
Other languages
English (en)
Inventor
Marcello Marchetti
Tommaso Iacoangeli
Giuseppe Biondi
Giovanni Battista Ciottoli
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39064326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2178850(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acraf filed Critical Acraf
Publication of PT2178850E publication Critical patent/PT2178850E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PT08775309T 2007-08-03 2008-07-23 Trazodona e cloridrato de trazodona na forma purificada PT2178850E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001603A ITMI20071603A1 (it) 2007-08-03 2007-08-03 Trazodone e trazodone cloridrato in forma purificata
US97653507P 2007-10-01 2007-10-01

Publications (1)

Publication Number Publication Date
PT2178850E true PT2178850E (pt) 2014-10-07

Family

ID=39064326

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08775309T PT2178850E (pt) 2007-08-03 2008-07-23 Trazodona e cloridrato de trazodona na forma purificada

Country Status (23)

Country Link
US (19) US8133893B2 (pt)
EP (1) EP2178850B1 (pt)
JP (3) JP5635401B2 (pt)
KR (2) KR101505522B1 (pt)
CN (1) CN101772490B (pt)
AR (1) AR067773A1 (pt)
BR (1) BRPI0814448B8 (pt)
CA (1) CA2693095C (pt)
CY (1) CY1115666T1 (pt)
DK (1) DK2178850T3 (pt)
EA (1) EA017019B1 (pt)
ES (1) ES2517871T3 (pt)
GE (2) GEP20135915B (pt)
HK (1) HK1139405A1 (pt)
HR (1) HRP20140978T1 (pt)
IL (2) IL203294A (pt)
IT (1) ITMI20071603A1 (pt)
MX (1) MX2010001094A (pt)
PL (1) PL2178850T3 (pt)
PT (1) PT2178850E (pt)
SI (1) SI2178850T1 (pt)
UA (1) UA103597C2 (pt)
WO (1) WO2009019133A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN103853790B (zh) * 2012-12-06 2016-04-06 腾讯科技（深圳）有限公司 移动终端浏览器的上传信息处理方法及装置
WO2015110883A1 (en) * 2014-01-21 2015-07-30 Piramal Enterprises Limited An improved process for the preparation of trazodone and hydrochloride salt thereof
CN105777745A (zh) * 2016-03-29 2016-07-20 深圳市泛谷药业股份有限公司 一种盐酸曲唑酮的制备方法
JP7301858B2 (ja) * 2018-02-07 2023-07-03 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ トラゾドンの調製のための継続的なプロセス
RU2706700C1 (ru) 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Фармацевтическая композиция для коррекции поведения кошек и собак в стрессовых ситуациях
CN117517545A (zh) * 2023-12-08 2024-02-06 重庆锐恩医药有限公司 一种盐酸曲唑酮有关物质检测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR8135E (pt)
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
GB1117068A (en) * 1965-12-15 1968-06-12 Acraf S-triazole-[4,3-a]-pyridine derivatives and processes for their preparation
FR8135M (pt) * 1968-12-31 1970-08-10
IT1047702B (it) * 1975-07-24 1980-10-20 Acraf Nuova sintesi degli psicofarmaci denominati trazodone ed eteroperidone
US4465683A (en) * 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) * 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones
IT1211095B (it) * 1981-08-17 1989-09-29 Roma Aziende Chimiche Riunite Impiego del trazodone nel trattamento delle ulcere gastroduodenali.
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
IT1314283B1 (it) * 1999-12-16 2002-12-06 Acraf Trazodone cloridrato ed un procedimento per prepararlo.
EA008705B1 (ru) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
CN101242856A (zh) * 2005-09-09 2008-08-13 莱博法姆公司 持续药物释放的组合物
ITMI20071573A1 (it) 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) * 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
US20140296250A1 (en) 2014-10-02
BRPI0814448B8 (pt) 2021-05-25
CA2693095C (en) 2015-11-24
US20140057922A1 (en) 2014-02-27
SI2178850T1 (sl) 2014-12-31
US20160324853A1 (en) 2016-11-10
ES2517871T3 (es) 2014-11-04
JP6513911B2 (ja) 2019-05-15
US20200253965A1 (en) 2020-08-13
JP2014221788A (ja) 2014-11-27
HK1139405A1 (en) 2010-09-17
US20160113926A1 (en) 2016-04-28
EA201070228A1 (ru) 2010-06-30
CN101772490A (zh) 2010-07-07
US8314236B2 (en) 2012-11-20
IL203294A (en) 2013-05-30
US20170333425A1 (en) 2017-11-23
JP5635401B2 (ja) 2014-12-03
EA017019B1 (ru) 2012-09-28
KR20100046245A (ko) 2010-05-06
KR20140133901A (ko) 2014-11-20
KR101505522B1 (ko) 2015-03-30
BRPI0814448B1 (pt) 2019-04-02
AR067773A1 (es) 2009-10-21
EP2178850B1 (en) 2014-09-03
UA103597C2 (en) 2013-11-11
US20240139179A1 (en) 2024-05-02
GEP20135915B (en) 2013-08-26
US20190231774A1 (en) 2019-08-01
US20120142699A1 (en) 2012-06-07
US20210052577A1 (en) 2021-02-25
US20130012520A1 (en) 2013-01-10
PL2178850T3 (pl) 2015-03-31
US20150105402A1 (en) 2015-04-16
BRPI0814448A2 (pt) 2016-07-26
MX2010001094A (es) 2010-03-01
US20170128442A1 (en) 2017-05-11
US8133893B2 (en) 2012-03-13
AU2008285779A1 (en) 2009-02-12
CN101772490B (zh) 2013-11-06
GEP20135926B (en) 2013-10-10
US20200038396A1 (en) 2020-02-06
HRP20140978T1 (hr) 2014-12-05
US20180161323A1 (en) 2018-06-14
IL225873A0 (en) 2013-06-27
WO2009019133A1 (en) 2009-02-12
JP2017141246A (ja) 2017-08-17
ITMI20071603A1 (it) 2009-02-04
US20150297589A1 (en) 2015-10-22
US20100056539A1 (en) 2010-03-04
US20130203771A1 (en) 2013-08-08
IL225873A (en) 2016-10-31
JP2010535170A (ja) 2010-11-18
US20180353503A1 (en) 2018-12-13
CY1115666T1 (el) 2017-01-25
EP2178850A1 (en) 2010-04-28
DK2178850T3 (en) 2014-11-17
CA2693095A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
HK1139405A1 (en) Trazodone and trazodone hydrochloride in purified form
EP2004302A4 (en) ELECTRETS AND COMPOUNDS USEFUL IN ELECTRETS
GB2443823B (en) Devices and methods for use in construction
PL2150617T3 (pl) Wzmocniona ekspresja i regiony stabilności
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
ZA201004261B (en) Anthelmintic agents and their use
IL247957A0 (en) Anti-ephrinb2 antibodies and methods of using them
GB2454413B (en) Improvements in shuttlecocks
IL208771A0 (en) Iminopyridine derivatives and use thereof
ZA200807614B (en) Buprenorphine derivatives and uses thereof
PL2503004T3 (pl) 17 alfa-propionian korteksolonu w I postaci krystalicznej
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP2213675A4 (en) PYRIDOOXAZEPINE DERIVATIVE AND USE THEREOF
IL199427A (en) Radiation-protective compounds and related methods
GB0621289D0 (en) Improvements in and relating to spectacles II
GB0605295D0 (en) Amino and derivatives
GB0619089D0 (en) Improvements in and relating to spectacles
GB0603717D0 (en) Electricity-generate and store
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
GB0714119D0 (en) Improvements in transistors
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES